Transient gestational hypothyroxinemia accelerates and enhances ulcerative colitis-like disorder in the male offspring
| dc.contributor.affiliation | Universidad Andres Bello | |
| dc.contributor.affiliation | Pontificia Universidad Catolica de Chile | |
| dc.contributor.affiliation | Universidad de Las Americas - Chile | |
| dc.contributor.affiliation | Universidad Autonoma de Chile | |
| dc.contributor.affiliation | Institut National de la Sante et de la Recherche Medicale (Inserm) | |
| dc.contributor.affiliation | Nantes Universite | |
| dc.contributor.author | Rivera, Juan Carlos | |
| dc.contributor.author | Opazo, Ma. Cecilia | |
| dc.contributor.author | Hernandez-Armengol, Rosario | |
| dc.contributor.author | Alvarez, Oscar | |
| dc.contributor.author | Mendoza-Leon, Maria Jose | |
| dc.contributor.author | Caamano, Esteban | |
| dc.contributor.author | Gatica, Sebastian | |
| dc.contributor.author | Bohmwald, Karen | |
| dc.contributor.author | Bueno, Susan M. | |
| dc.contributor.author | Gonzalez, Pablo A. | |
| dc.contributor.author | Neunlist, Michel | |
| dc.contributor.author | Boudin, Helene | |
| dc.contributor.author | Kalergis, Alexis M. | |
| dc.contributor.author | Riedel, Claudia A. | |
| dc.date.accessioned | 2024-01-29T18:38:02Z | |
| dc.date.available | 2024-01-29T18:38:02Z | |
| dc.date.issued | 2024-01-04 | |
| dc.description.abstract | Introduction Gestational hypothyroxinemia (HTX) is a condition that occurs frequently at the beginning of pregnancy, and it correlates with cognitive impairment, autism, and attentional deficit in the offspring. Evidence in animal models suggests that gestational HTX can increase the susceptibility of the offspring to develop strong inflammation in immune-mediated inflammatory diseases. Ulcerative colitis (UC) is a frequent inflammatory bowel disease with unknown causes. Therefore, the intensity of ulcerative colitis-like disorder (UCLD) and the cellular and molecular factors involved in proinflammatory or anti-inflammatory responses were analyzed in the offspring gestated in HTX (HTX-offspring) and compared with the offspring gestated in euthyroidism (Control-offspring). Methods Gestational HTX was induced by the administration of 2-mercapto-1-methylimidazole in drinking water to pregnant mice during E10–E14. The HTX-offspring were induced with UCLD by the acute administration of dextran sodium sulfate (DSS). The score of UCLD symptomatology was registered every day, and colon histopathology, immune cells, and molecular factors involved in the inflammatory or anti-inflammatory response were analyzed on day 6 of DSS treatment. Results The HTX-offspring displayed earlier UCLD pathological symptoms compared with the Control-offspring. After 6 days of DSS treatment, the HTX-offspring almost doubled the score of the Control-offspring. The histopathological analyses of the colon samples showed signs of inflammation at the distal and medial colon for both the HTX-offspring and Control-offspring. However, significantly more inflammatory features were detected in the proximal colon of the HTX-offspring induced with UCLD compared with the Control-offspring induced with UCLD. Significantly reduced mRNA contents encoding for protective molecules like glutamate-cysteine ligase catalytic subunit (GCLC) and mucin-2 (MUC-2) were found in the colon of the HTX-offspring as compared with the Control-offspring. Higher percentages of Th17 lymphocytes were detected in the colon tissues of the HTX-offspring induced or not with UCLD as compared with the Control-offspring. Discussion Gestational HTX accelerates the onset and increases the intensity of UCLD in the offspring. The low expression of MUC-2 and GCLC together with high levels of Th17 Lymphocytes in the colon tissue suggests that the HTX-offspring has molecular and cellular features that favor inflammation and tissue damage. These results are important evidence to be aware of the impact of gestational HTX as a risk factor for UCLD development in offspring. | |
| dc.description.sponsorship | Millennium Institute on Immunology and Immunotherapy PROGRAMA ICM -ANID [ICN2021_045]; FONDECYT [1191300, 1231905, 1231851, 1212075, 11221280]; FONDEF/IDeA [ID20I10082]; PUENTE-2023-18; ANID [21211419, 21202356]; The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Millennium Institute on Immunology and Immunotherapy PROGRAMA ICM -ANID, ICN2021_045; FONDECYT #1191300, #1231905, #1231851, #1212075, and #11221280; FONDEF/IDeA ID20I10082, and PUENTE-2023-18. MM and EC thanks to ANID for providing a Ph.D. Scholarship [21211419 and 21202356, respectively]. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Frontiers in Endocrinology, 14, 1269121. https://doi.org/10.3389/fendo.2023.1269121 | |
| dc.identifier.doi | https://doi.org/10.3389/fendo.2023.1269121 | |
| dc.identifier.folio | 11221280 | |
| dc.identifier.folio | 1191300 | |
| dc.identifier.folio | 1212075 | |
| dc.identifier.folio | 1231851 | |
| dc.identifier.folio | 1231905 | |
| dc.identifier.folio | 21211419 | |
| dc.identifier.folio | 21202356 | |
| dc.identifier.issn | 1664-2392 | |
| dc.identifier.orcid | https://orcid.org/0000-0002-6794-7544 | |
| dc.identifier.orcid | https://orcid.org/0000-0003-1892-5071 | |
| dc.identifier.orcid | https://orcid.org/0009-0004-5458-1012 | |
| dc.identifier.orcid | https://orcid.org/0000-0002-9714-2384 | |
| dc.identifier.orcid | https://orcid.org/0000-0003-4263-9294 | |
| dc.identifier.pmid | 38239991 | |
| dc.identifier.researcherid | JQX-2530-2023 | |
| dc.identifier.researcherid | KSL-5357-2024 | |
| dc.identifier.researcherid | AAF-2934-2021 | |
| dc.identifier.researcherid | L-1973-2013 | |
| dc.identifier.researcherid | F-5669-2012 | |
| dc.identifier.researcherid | K-2388-2015 | |
| dc.identifier.researcherid | K-2400-2015 | |
| dc.identifier.researcherid | HOH-2917-2023 | |
| dc.identifier.ror | https://ror.org/01qq57711 | |
| dc.identifier.ror | https://ror.org/04teye511 | |
| dc.identifier.ror | https://ror.org/05j6ybs54 | |
| dc.identifier.ror | https://ror.org/010r9dy59 | |
| dc.identifier.ror | https://ror.org/02vjkv261 | |
| dc.identifier.ror | https://ror.org/01kbkse74 | |
| dc.identifier.ror | https://ror.org/03gnr7b55 | |
| dc.identifier.ror | https://ror.org/0166e9x11 | |
| dc.identifier.scopusauthorid | 55360870100 | |
| dc.identifier.scopusauthorid | 55966517500 | |
| dc.identifier.scopusauthorid | 58614598300 | |
| dc.identifier.scopusauthorid | 58814104700 | |
| dc.identifier.scopusauthorid | 57221338973 | |
| dc.identifier.scopusauthorid | 60641492000 | |
| dc.identifier.scopusauthorid | 59805807300 | |
| dc.identifier.scopusauthorid | 40260992400 | |
| dc.identifier.scopusauthorid | 7003686736 | |
| dc.identifier.scopusauthorid | 57206413101 | |
| dc.identifier.scopusauthorid | 6701416352 | |
| dc.identifier.scopusauthorid | 6602785341 | |
| dc.identifier.scopusauthorid | 6601943684 | |
| dc.identifier.scopusauthorid | 24764954100 | |
| dc.identifier.uri | https://repositorio.udla.cl/handle/udla/1181 | |
| dc.language.iso | eng | |
| dc.publisher | FRONTIERS MEDIA SA | |
| dc.relation.funding | Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT, (11221280, 1191300, 1212075, 1231851, 1231905, FONDEF/IDeA ID20I10082, PUENTE-2023-18) | |
| dc.relation.funding | Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT | |
| dc.relation.funding | Millennium Institute on Immunology and Immunotherapy PROGRAMA ICM -ANID [ICN2021_045] | |
| dc.relation.funding | FONDECYT [1191300, 1231905, 1231851, 1212075, 11221280] | |
| dc.relation.funding | FONDEF/IDeA [ID20I10082] | |
| dc.relation.funding | PUENTE-2023-18 | |
| dc.relation.funding | ANID [21211419, 21202356] | |
| dc.relation.isindexedby | Web of Science | |
| dc.relation.issn | 1664-2392 | |
| dc.rights | Creative Commons Attribution 4.0 International | |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.source | FRONTIERS IN ENDOCRINOLOGY | |
| dc.source.uri | https://doi.org/10.3389/fendo.2023.1269121 | |
| dc.subject | gestational hypothyroxinemia | |
| dc.subject | ulcerative colitis | |
| dc.subject | colon inflammation | |
| dc.subject | immune cells | |
| dc.subject | autoimmunity | |
| dc.subject | radical oxygen species | |
| dc.subject.lcsh | Colitis ulcerativa. | |
| dc.subject.lcsh | Autoinmunidad. | |
| dc.subject.lcsh | Autoimmunity. | |
| dc.title | Transient gestational hypothyroxinemia accelerates and enhances ulcerative colitis-like disorder in the male offspring | |
| dc.title.alternative | Transient gestational hypothyroxinemia accelerates and enhances ulcerative colitis-like disorder in the male offspring. | |
| dc.type | journal article | |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | |
| dc.type.driver | info:eu-repo/semantics/article | |
| oaire.citation.title | FRONTIERS IN ENDOCRINOLOGY | |
| oaire.citation.volume | 14 | |
| oaire.fundingReference.awardNumber | 11221280 | |
| oaire.fundingReference.awardNumber | 1191300 | |
| oaire.fundingReference.awardNumber | 1212075 | |
| oaire.fundingReference.awardNumber | 1231851 | |
| oaire.fundingReference.awardNumber | 1231905 | |
| oaire.fundingReference.awardNumber | 21211419 | |
| oaire.fundingReference.awardNumber | 21202356 | |
| oaire.fundingReference.funderName | Agencia Nacional de Investigación y Desarrollo (ANID) | |
| udla.curacion.control | jmvg | |
| udla.oecd.area | 3 Ciencias Médicas y de la Salud | |
| udla.oecd.discipline | 3.1.9 Patología | |
| udla.oecd.subarea | 3.1 Medicina Básica |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Rivera et al 2024 Transient gestational hypothyroxinemia accelerates and enhances ulcerative colitis-like disorder in the male offspring.pdf
- Size:
- 9.38 MB
- Format:
- Adobe Portable Document Format
- Description:
- Rivera et al 2024 Transient gestational hypothyroxinemia accelerates and enhances ulcerative colitis-like disorder in the male offspring
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: